RETATRUTIDE — Advanced Triple Receptor Agonist for Metabolic Research

Investigational Peptide | GLP-1, GIP & Glucagon Receptor Agonist | Obesity & Metabolic Research

Product Overview

Retatrutide is an innovative investigational peptide developed by Eli Lilly that simultaneously targets three metabolic hormone receptors: GLP-1, GIP, and glucagon.

This triple receptor agonist is being investigated for its potential in obesity management, type 2 diabetes, and metabolic regulation.

By activating multiple hormonal pathways involved in appetite control, glucose metabolism, and energy expenditure, retatrutide represents an emerging approach to metabolic research.

Mechanism of Action

Retatrutide combines three complementary mechanisms:

• GLP-1 Receptor Activation: Influences appetite regulation, increases satiety, and supports glucose-dependent insulin secretion.

• GIP Receptor Activation: Contributes to glucose regulation and metabolic signaling.

• Glucagon Receptor Activation: Influences hepatic energy metabolism and may contribute to increased energy expenditure.

• Metabolic Homeostasis: The combined activation of these receptors is being investigated for its effects on body weight, glucose control, and energy balance.

Clinical Research & Findings

Clinical investigations have reported substantial weight reduction in selected study populations.

In a Phase II trial, participants receiving the highest studied dose achieved an average body weight reduction of up to 24.2% over 48 weeks.

These findings have supported further investigation through advanced Phase III clinical trials.

However, trial results should not be interpreted as guaranteed individual outcomes or definitive proof of superiority over all currently available weight-management treatments.

Potential Research Applications

• Obesity Research: Investigation of metabolic and hormonal pathways involved in body weight regulation.

• Type 2 Diabetes Research: Evaluation of glucose homeostasis and insulin-related metabolic responses.

• Energy Expenditure: Exploration of metabolic processes associated with energy utilization.

• Appetite Regulation: Research into hormonal mechanisms affecting hunger and satiety.

• Metabolic Health: Investigation of obesity-related metabolic complications.

Development Status & Safety

Retatrutide remains an investigational pharmaceutical compound undergoing advanced clinical development, including Phase III trials.

It is not approved for routine clinical use.

Reported adverse events in clinical studies have commonly included gastrointestinal symptoms such as nausea, vomiting, and diarrhea.

Further research is required to fully establish its long-term safety, effectiveness, and benefit-risk profile across different patient populations.

Research Use Only

FOR AUTHORIZED SCIENTIFIC AND CLINICAL RESEARCH PURPOSES ONLY.

Intended exclusively for qualified professionals conducting legitimate scientific investigations and appropriately authorized clinical research.

Not approved for general human or veterinary use. Not intended for personal injection, self-administration, or unsupervised therapeutic applications.

Research-use labeling does not replace applicable regulatory authorization requirements.

PEPTITAN — PRECISION. SCIENCE. RESEARCH.